|
|
||||||||||||||
|
|
|||||||||||||||
DYSPEPSIA MANAGEMENT |
1 Division of Gastroenterology, Dalhousie University, Halifax, Nova Scotia, Canada
2 Department of Medicine, University of Sydney, Nepean Hospital, Penrith, Australia
3 Division of Gastroenterology, Department of Medicine, University Hospital, Lausanne, Switzerland
4 Department of Biomedicine and Surgery, University Hospital, Linköping, Sweden
5 AstraZeneca R&D, Mölndal, Sweden
Correspondence to:
Correspondence to:
Dr S J O Veldhuyzen van Zanten, Division of Gastroenterology, Dalhousie University, Queen Elizabeth II Health Science Centre, Victoria General Site, Room 928, Centennial Building, Halifax, Nova Scotia, Canada B3H 2YG;
zanten{at}is.dal.ca
ABSTRACT
Currently, one of the most important unresolved questions concerning Helicobacter pylori is whether eradication of the organism leads to a sustained improvement in symptoms in patients diagnosed with functional (non-ulcer) dyspepsia. Recently, two very similar studies, the ORCHID and OCAY studies, have been completed and the combined results of these two multicentre, multinational, randomised, double blind, controlled clinical trials are reviewed.
Keywords: clinical trial; dyspepsia; Helicobacter pylori; OCAY study; ORCHID study; quality of life; symptom relief
Abbreviations: GDSS, Glasgow dyspepsia severity score; GORD, gastro-oesophageal reflux disease; GSRS, gastrointestinal symptom rating scale; ITT, intention to treat; MRC, Medical Research Council; OAC, omeprazole 20 mg twice daily, amoxycillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for seven days; PGWB, psychological general well being
This article has been cited by other articles:
![]() |
D I Campbell and J E Thomas Helicobacter pylori infection in paediatric practice Arch. Dis. Child. Ed. Pract., August 1, 2005; 90(2): ep25 - ep30. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |